Clinical
RSSArticles
-
Pessaries in Patients with Short Cervices
The largest multicenter, randomized, controlled trial so far has found no significant benefit of pessaries to prevent preterm birth or to decrease neonatal morbidity in patients with short cervices.
-
Early Initiation of Postmenopausal Estrogen Therapy
Women randomized to oral estradiol therapy showed less progression of subclinical atherosclerosis than those who received placebo.
-
Clinical Briefs
In this section: watching carefully for suicide risk; tackling chronic cough; and a new treatment for Peyronie's disease.
-
Reslizumab Injection (Cinqair)
Reslizumab is indicated for add-on maintenance treatment of adult patients with severe asthma with eosinophilic phenotype.
-
Longer Course Therapy for Lyme Disease Is Not Beneficial
A randomized, placebo-controlled clinical trial from the Netherlands found that longer-term antibiotic therapy for Lyme disease did not improve health-related quality of life compared to a standard course of treatment.
-
Predicting Seizure Recurrence with Routine EEG After First Unprovoked Seizure
Using positive likelihood ratios, an adult and child with epileptiform discharges on electroencephalography were estimated to have a 77% and 66% probability, respectively, of recurrent seizures.
-
Too Much of a Good Thing
In the United States in 2010 and 2011, an estimated 30% of outpatient oral antibiotic prescriptions may have been inappropriate, a finding that supports the need for establishing a goal for outpatient antibiotic stewardship.
-
Pioglitazone and Secondary Cardiovascular Prevention
Might a pharmacologic agent that improves insulin resistance be effective in secondary prevention of cardiovascular events?
-
An Infectious Disease Causes Pathological Aggression?
A recent study found that positive Toxoplasma gondii sero-status was statistically significantly associated with aggression.
-
Subclinical Thyroid Disease Associated with Increased Mortality in Seniors
In a population of subjects with subclinical hypothyroidism, a thyroid stimulating hormone > 6.35 mIU/L was the threshold for increasing mortality risk.